Cargando…

Prevalence of carbapenemase genes among carbapenem-nonsusceptible Enterobacterales collected in US hospitals in a five-year period and activity of ceftazidime/avibactam and comparator agents

OBJECTIVES: To evaluate the prevalence of acquired β-lactamase genes and susceptibility profiles of carbapenem-nonsusceptible Enterobacterales (CNSE) clinical isolates collected in US hospitals during a 5-year period. METHODS: Isolates were susceptibility tested by reference broth microdilution meth...

Descripción completa

Detalles Bibliográficos
Autores principales: Castanheira, Mariana, Deshpande, Lalitagauri M, Mendes, Rodrigo E, Doyle, Timothy B, Sader, Helio S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524567/
https://www.ncbi.nlm.nih.gov/pubmed/36196444
http://dx.doi.org/10.1093/jacamr/dlac098
_version_ 1784800528993091584
author Castanheira, Mariana
Deshpande, Lalitagauri M
Mendes, Rodrigo E
Doyle, Timothy B
Sader, Helio S
author_facet Castanheira, Mariana
Deshpande, Lalitagauri M
Mendes, Rodrigo E
Doyle, Timothy B
Sader, Helio S
author_sort Castanheira, Mariana
collection PubMed
description OBJECTIVES: To evaluate the prevalence of acquired β-lactamase genes and susceptibility profiles of carbapenem-nonsusceptible Enterobacterales (CNSE) clinical isolates collected in US hospitals during a 5-year period. METHODS: Isolates were susceptibility tested by reference broth microdilution methods. Results were interpreted using CLSI breakpoints. Isolates displaying nonsusceptible MICs for imipenem or meropenem were categorized as CNSE. CNSE isolates were screened for β-lactamase-encoding genes using whole-genome sequencing. New genes were cloned, expressed in an Escherichia coli background and susceptibility tested. RESULTS: A total of 450 (1.3%) isolates were CNSE. Klebsiella pneumoniae serine carbapenemase (KPC) production was the most common resistance mechanism among CNSE isolates: 281/450 (62.4%) carried bla(KPC), including three new variants. OXA-48-like and metallo-β-lactamase (MBL) encoding genes were detected among seven and 12 isolates, respectively. Among MBL genes, bla(NDM-1) was the most common, but bla(NDM-5), bla(VIM-1) and bla(IMP-27) were also identified. 169 (37.6% of the CNSE) isolates did not produce carbapenemases. Ceftazidime/avibactam was the most active agent (95.0% to 100.0% susceptible) against CNSE isolates from all carbapenemase groups except MBL-producing isolates. Ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam inhibited 100.0%, 97.6% and 92.3% of the non-carbapenemase CNSE isolates, respectively. Among the three new bla(KPC) variants, one conferred resistance to ceftazidime/avibactam and low meropenem MIC results while the other two had profiles similar to bla(KPC-2) or bla(KPC-3). CONCLUSIONS: A decline in carbapenemase production was noticed in US hospitals in the 5-year period analysed in this study. New β-lactam/β-lactamase inhibitor combinations tested had good activity against CNSE isolates.
format Online
Article
Text
id pubmed-9524567
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-95245672022-10-03 Prevalence of carbapenemase genes among carbapenem-nonsusceptible Enterobacterales collected in US hospitals in a five-year period and activity of ceftazidime/avibactam and comparator agents Castanheira, Mariana Deshpande, Lalitagauri M Mendes, Rodrigo E Doyle, Timothy B Sader, Helio S JAC Antimicrob Resist Original Article OBJECTIVES: To evaluate the prevalence of acquired β-lactamase genes and susceptibility profiles of carbapenem-nonsusceptible Enterobacterales (CNSE) clinical isolates collected in US hospitals during a 5-year period. METHODS: Isolates were susceptibility tested by reference broth microdilution methods. Results were interpreted using CLSI breakpoints. Isolates displaying nonsusceptible MICs for imipenem or meropenem were categorized as CNSE. CNSE isolates were screened for β-lactamase-encoding genes using whole-genome sequencing. New genes were cloned, expressed in an Escherichia coli background and susceptibility tested. RESULTS: A total of 450 (1.3%) isolates were CNSE. Klebsiella pneumoniae serine carbapenemase (KPC) production was the most common resistance mechanism among CNSE isolates: 281/450 (62.4%) carried bla(KPC), including three new variants. OXA-48-like and metallo-β-lactamase (MBL) encoding genes were detected among seven and 12 isolates, respectively. Among MBL genes, bla(NDM-1) was the most common, but bla(NDM-5), bla(VIM-1) and bla(IMP-27) were also identified. 169 (37.6% of the CNSE) isolates did not produce carbapenemases. Ceftazidime/avibactam was the most active agent (95.0% to 100.0% susceptible) against CNSE isolates from all carbapenemase groups except MBL-producing isolates. Ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam inhibited 100.0%, 97.6% and 92.3% of the non-carbapenemase CNSE isolates, respectively. Among the three new bla(KPC) variants, one conferred resistance to ceftazidime/avibactam and low meropenem MIC results while the other two had profiles similar to bla(KPC-2) or bla(KPC-3). CONCLUSIONS: A decline in carbapenemase production was noticed in US hospitals in the 5-year period analysed in this study. New β-lactam/β-lactamase inhibitor combinations tested had good activity against CNSE isolates. Oxford University Press 2022-09-30 /pmc/articles/PMC9524567/ /pubmed/36196444 http://dx.doi.org/10.1093/jacamr/dlac098 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Original Article
Castanheira, Mariana
Deshpande, Lalitagauri M
Mendes, Rodrigo E
Doyle, Timothy B
Sader, Helio S
Prevalence of carbapenemase genes among carbapenem-nonsusceptible Enterobacterales collected in US hospitals in a five-year period and activity of ceftazidime/avibactam and comparator agents
title Prevalence of carbapenemase genes among carbapenem-nonsusceptible Enterobacterales collected in US hospitals in a five-year period and activity of ceftazidime/avibactam and comparator agents
title_full Prevalence of carbapenemase genes among carbapenem-nonsusceptible Enterobacterales collected in US hospitals in a five-year period and activity of ceftazidime/avibactam and comparator agents
title_fullStr Prevalence of carbapenemase genes among carbapenem-nonsusceptible Enterobacterales collected in US hospitals in a five-year period and activity of ceftazidime/avibactam and comparator agents
title_full_unstemmed Prevalence of carbapenemase genes among carbapenem-nonsusceptible Enterobacterales collected in US hospitals in a five-year period and activity of ceftazidime/avibactam and comparator agents
title_short Prevalence of carbapenemase genes among carbapenem-nonsusceptible Enterobacterales collected in US hospitals in a five-year period and activity of ceftazidime/avibactam and comparator agents
title_sort prevalence of carbapenemase genes among carbapenem-nonsusceptible enterobacterales collected in us hospitals in a five-year period and activity of ceftazidime/avibactam and comparator agents
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524567/
https://www.ncbi.nlm.nih.gov/pubmed/36196444
http://dx.doi.org/10.1093/jacamr/dlac098
work_keys_str_mv AT castanheiramariana prevalenceofcarbapenemasegenesamongcarbapenemnonsusceptibleenterobacteralescollectedinushospitalsinafiveyearperiodandactivityofceftazidimeavibactamandcomparatoragents
AT deshpandelalitagaurim prevalenceofcarbapenemasegenesamongcarbapenemnonsusceptibleenterobacteralescollectedinushospitalsinafiveyearperiodandactivityofceftazidimeavibactamandcomparatoragents
AT mendesrodrigoe prevalenceofcarbapenemasegenesamongcarbapenemnonsusceptibleenterobacteralescollectedinushospitalsinafiveyearperiodandactivityofceftazidimeavibactamandcomparatoragents
AT doyletimothyb prevalenceofcarbapenemasegenesamongcarbapenemnonsusceptibleenterobacteralescollectedinushospitalsinafiveyearperiodandactivityofceftazidimeavibactamandcomparatoragents
AT saderhelios prevalenceofcarbapenemasegenesamongcarbapenemnonsusceptibleenterobacteralescollectedinushospitalsinafiveyearperiodandactivityofceftazidimeavibactamandcomparatoragents